EZH2 and Hepatic fibrosis: Therapeutic promise to target EZH2 function in a cell context-dependent manner in the liver is provided by a study using an antibody-liposome-DZNeP that was targeted specifically to HSCs and found effective in blocking the fibrotic response in an in vivo CCl4-induced liver fibrosis mouse model (Zeybel et al., 2017).